What is pathophysiology of Prostate cancer?

['ነዚ ገጽ ስምዓዮ']

ናይ ፕሮስቴት ካንሰር ፓቶፊዚዮሎጂ እንታይ እዩ?

ናይ ፕሮስቴት ካንሰር ፓቶፊዚዮሎጂ ነቲ ናይ ሕማም ምዕባለን ምዕባለን ዘምጽእ መሰረታዊ ኣሰራርሓን መስርሕን የመልክት።

ናይ ፕሮስቴት ካንሰር ካብ ዋህዮታት ናይ ፕሮስቴት ግላንድ ዝምንጭው ሕማቕ መንሽሮ እዩ፡ እዚ ድማ ኣብ ደቂ ተባዕትዮ ኣብ ትሕቲ ናይ ጡብ መሽኒ ዝርከብ ብቅርጺ ዎልነት ዝቑጸር ንእሽቶ ኣካል እዩ።

ፕሮስታታ ዘርኢ ዘርኢ ዘዳሉ እንትኾን ዘርኢ ዘርኢ ዘድልዮ መግብን ዘርኢ ዘርኢ ዝጓዓዓዘሉን እዩ።

እቲ ልክዕ ጠንቂ ናይ ፕሮስቴት ካንሰር ምሉእ ብምሉእ ኣይተረድአን፣ እንተኾነ ግን ብዙሓት ረቛሒታት ነቲ ሕማም ናይ ምምዕባል ሓደጋ ከም ዝውስኽዎ ይፍለጥ።

እዚኦም ዕድመ፣ ታሪኽ ስድራቤት፣ ዓሌት፣ ከምኡ'ውን ገለ ጀነቲካዊ ምዩቴሽን የጠቓልሉ።

መንሽሮ ፕሮስቴት ኣብ ብዕድመ ዝደፍኡ ደቂ ተባዕትዮ ልሙድ ኮይኑ፡ መብዛሕትኦም ግዳያት ድማ ኣብ ልዕሊ 65 ዓመት ዝዕድሚኦም ደቂ ተባዕትዮ ይርከቡ።

ብተወሳኺ፡ ኣብ ስድራ ቤት ናይ ፕሮስቴት ካንሰር ታሪኽ ዘለዎም ሰብኡት፡ ከም ጸለምቲ ኣመሪካውያንን ካሪብያንን ዝኣመሰሉ ሰባት ኣብ ዝለዓለ ሓደጋ ይርከቡ።

ናይ ፕሮስቴት ካንሰር ፓቶፊዚዮሎጂ ኣብ ውሽጢ ፕሮስቴት ግላንድ ዘይቁፅፅር ዕብየትን ክፍፍል ዋህዮታትን ዘጠቓለለ እዩ።

እዚ ብሰንኪ ናይ ገለ ናይ ዕብየት ረቛሒታት ወይ ናይ ቱሞር መቆጻጸሪ ጂንታት ዘይምጥቃም ዘስዕቡ ናይ ጂን ምቅይያራት ከጋጥም ይኽእል።

እዞም ምዩቴሽን ኣብ ዘይምቁጽጻር ዕብየት ዋህዮታት ከም ውጽኢት ክኾኑ ይኽእሉ፡ እዚ ድማ ናብ ምምስራት መንሽሮ ይመርሕ።

እቲ መንሽሮ እናዓበየ ምስ ዝኸይድ፡ ኣብ ከባቢኡ ንዝርከቡ ጨናፍርን ኣካላትን፡ ከም ናይ ሽንቲ ቦርሳ፡ ናይ ኣፍ ደገ ማህጸን ከምኡ'ውን ኣብ ከባቢኡ ንዝርከቡ ናይ ሊምፍ ኖድስ ክወሩ ይኽእሉ።

ኣብ ገለ ኣጋጣሚታት ናይ ካንሰር ዋህዮታት ካብቲ ናይ መጀመርያ መንሽሮ ክፈልዩን ናብ ካልእ ክፋላት ናይ ኣካላት ብደም ወይ ሊምፋቲክ ሲስተም ክዝርጋሕን ይኽእሉ። እዚ መስርሕ ሜታስታሲስ ተባሂሉ ይፍለጥ።

እቲ መንሽሮ ምስ ተዘርገሐ፡ ንምሕካሙ ኣጸጋሚ ክኸውን ይኽእል እዩ።

ናይ ፕሮስቴት ካንሰር ብ ሆርሞናዊ ረቛሒታት ብፍላይ ድማ ብ ኣንድሮጅን ሆርሞን ቴስቶስትሮን ክጽሎ ይኽእል እዩ።

ቴስቶስትሮን ናይ ፕሮስቴት ካንሰር ዋህዮታት ክዓብዩ ክደፋፍእ ይኽእል እዩ፡ ብዙሓት ናይ ፕሮስቴት ካንሰር ሕክምናታት ድማ ነቲ መጠን ናይዚ ሆርሞን ንምንካይ ወይ ሳዕቤናቱ ንምዕጋት ዝዓለመ እዩ።

ብሓጺሩ፡ ናይ ፕሮስቴት ካንሰር ፓቶፊዚዮሎጂ ኣብ ውሽጢ ፕሮስቴት ግላንድ ዘሎ ዘይቁጽጽር ዕብየትን ክፍፍል ዋህዮታትን ዘጠቓልል እዩ፡ እዚ ድማ ብጀነቲካዊ፡ ሆርሞናላዊን ከባቢያዊን ረቛሒታት ክጽሎ ይኽእል።

ነቲ ሕማም ዝፈጥርዎ መሰረታዊ ሜካኒዝም ምርዳእ፡ ውጽኢታዊ ዝኾነ ሕክምና ንምምዕባልን ውጽኢት ናይቶም ናይ ፕሮስቴት ካንሰር ዘለዎም ሕሙማት ንምምሕያሽን ኣዝዩ ኣገዳሲ እዩ።

['መወከሲ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.

Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.

Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.

Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.

Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.

Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.

['ናይ ተሓታትነት መግለጺ: ሕክምናዊ']

['እዚ ወብ ሳይት ንትምህርትን ሓበሬታን ጥራይ እዩ ተዋሂቡ: ሕክምናዊ ምኽሪ ወይ ሞያዊ ኣገልግሎት ንምሃብ ተባሂሉ እተዳለወ ድማ ኣይኰነን።']

['እቲ ሓበሬታ ንዝኾነ ናይ ጥዕና ጸገም ወይ ሕማም ንምፍላጥ ወይ ንምሕካም ክውዕል የብሉን፣ እቶም ውልቃዊ ናይ ሕክምና ምኽሪ ዝደልዩ ድማ ምስ ፍቓድ ዘለዎ ሓኪም ክማኸሩ ኣለዎም።']

['እቲ መልሲ ናይቶም ሕቶታት ዝህብ ኔቭራል ኔት፡ ብፍላይ ኣብ ቁጽሪ ዝተሞርኮሰ ሓበሬታ፡ ንኣብነት፡ ብዝሒ ናይቶም ዝተለኽፉ ሰባት ምስ ዝኸውን፡ ኣዝዩ ዘይቅኑዕ ምዃኑ ኣስተብህል።']

['ኩሉ ግዜ ብዛዕባ ናይ ጥዕና ኩነታትካ ምኽሪ ናይ ሓኪምካ ወይ ካልእ ብቑዕ ናይ ጥዕና ኣገልጋሊ ድለ። ኣብዚ መርበብ ሓበሬታ ዘንበብካዮ ነገር ምኽንያት ናይ ሞያ ናይ ሕክምና ምኽሪ ዕሽሽ ኣይትበል። ናይ ሕክምና ህጹጽ ኩነታት ከጋጥመካ ይኽእል እዩ ኢልካ እንተሓሲብካ 911 ደውል ወይ ናብ ዝቐረበ ህጹጽ ክፍሊ ህጹጽ ረድኤት ብቅልጡፍ ኪድ። እዚ መርበብ ሓበሬታ ወይ ኣጠቓቕምኡ ናይ ሓኪምን ሕሙምን ርክብ ኣይፈጥርን። BioMedLib ወይ ሰራሕተኛታቱ ወይ ዝኾነ ኣበርካቲ ናይዚ መርበብ ሓበሬታ እዚ ኣብዚ ዝተዋህበ ሓበሬታ ወይ ኣጠቓቕምኡ ብዝምልከት ዝኾነ ይኹን መግለጺ ወይ ውክልና ኣይህብን እዩ።']

['ናይ መሰል ተሓታትነት']

['ናይ 1998 ዲጂታል ሚሊኒየም ሕጊ መሰል ደራሲ 17 U.S.C. § 512 (the DMCA) ኣብ ኢንተርኔት ዝረአ ዘሎ ትሕዝቶ ብመሰረት ሕጊ መሰል ደራሲ ኣሜሪካ መሰሎም ዝጥሕስ እዩ ኢሎም ንዝኣምኑ ወነንቲ መሰል ደራሲ ይምልከት። ']

['ዝኾነ ትሕዝቶ ወይ ማተርያል ምስ ዌብሳይትና ወይ ኣገልግሎትና ብምትሕሓዝ ዝተዳለወ ንናይ መሰል ዋንነትካ ዝጥሕስ እዩ ኢልካ ብጽቡቕ እምነት እንተኣሚንካ፣ ንስኻ (ወይ ወኪልካ) ነቲ ትሕዝቶ ወይ ማተርያል ክውገድ ወይ ድማ ናብኡ ምእታው ክኽልከል ዝሓትት ምልክታ ክትልእኸልና ትኽእል ኢኻ።']

['እቲ ምልክታ ብጽሑፍ ብኢሜይል ክለኣኽ ኣለዎ (ናይ ኢሜይል ኣድራሻ ንምርካብ ኣብ "Contact" ዝብል ክፋል ተመልከት) ።']

['እቲ DMCA እዚ ዝስዕብ ሓበሬታታት ክካተት ይሓትት፡ (1) መግለጺ ናይቲ ግህሰት ተፈጻምነት ኣለዎ ተባሂሉ ዝሕመ፡ (2) መግለጺ ናይቲ ግህሰት ተፈጻምነት ኣለዎ ተባሂሉ ዝሕመ ትሕዝቶን ነቲ ትሕዝቶ ክንረኽቦ ዘኽእለና እኹል ሓበሬታን (3) ናይ ርክብ ሓበሬታ፡ እንተላይ ኣድራሻኻ፡ ቁጽሪ ተሌፎንካን ናይ ኢመይል ኣድራሻኻን (4) እቲ ትሕዝቶ በቲ ጥርዓን ዝቐርበሉ መገዲ በቲ በዓል መሰል፡ ወይ ወኪሉ ወይ ብዝኾነ ሕጊ ከምዘይፍቀድ ጽቡቕ እምነት ከም ዘሎካ ዝገልጽ መግለጺ፡']

['(5) እቲ ኣብ ምልክታ ዘሎ ሓበሬታ ልክዕ ምዃኑን ነቲ ዝተጣሕሰ መሰል ናይ ምጥባቕ ስልጣን ከምዘለካን ብገበን ናይ ሓሶት ምስክርነት ዝተፈረመ መግለጺኻ፣']

["ከምኡ'ውን (6) ናይ ዋና መሰል ደራሲ ወይ ብስም ዋና መሰል ደራሲ ክሰርሕ ዝተፈቕደሉ ሰብ፡ ኣካላዊ ወይ ኤለክትሮኒካዊ ፊርማ። "]

['እዚ ኩሉ ኣብ ላዕሊ ዝተጠቕሰ ሓበሬታ ዘይምምላእ ነቲ ጥርዓንካ ናይ ምምላስ መስርሕ ክድንጉዮ ይኽእል እዩ።']

['ርክብ']

['ዝኾነ ሕቶ / ሓሳብ ምስ ዝህልወኩም ብኢሜይል ስደዱልና።']

What is pathophysiology of prostate cancer?

The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.

Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.

The prostate gland produces seminal fluid, which nourishes and transports sperm.

The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.

These include age, family history, race, and certain genetic mutations.

Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.

Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.

The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.

This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.

These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.

As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.

In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.

Once the cancer has spread, it can be more difficult to treat.

Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.

Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.

In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.

Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ብዛዕባ']

['BioMedLib ሕቶን መልስን ንምፍጣር ኣውቶማቲክ ኮምፒዩተራት (ማሽን-ሊንጊንግ ኣልጎሪዝም) ይጥቀም።']

["ካብ 35 ሚልዮን ናይ ባዮሜዲካል ጽሑፋት ናይ PubMed/Medline ጀሚርና፡ ከምኡ'ውን ናይ RefinedWeb ዌብሳይታት።"]

['ኣብ "References" ከምኡውን "Disclaimer" ተመልከት።']